Global Autoimmune Drugs Market
Market Outline: Autoimmune Drugs Market
The immune system protects the body from the infections and diseases. In autoimmune disorders low or overactivity may appear. There is no exact causes of autoimmune diseases are identified. In response to unknown trigger, immune system produces antibodies that instead of fighting infections, attacks body own tissues. There are more than 80 autoimmune diseases are there and diagnosis varies from disease to disease based on the type of disease..
Market Dynamics: Autoimmune Drugs Market
Global Autoimmune Drugs market is driven by government initiatives towards increasing awareness in public about autoimmune disorders. In addition, increase in R&D investments and rising prevalence of autoimmune disorders are expected to boost the global autoimmune disease diagnostics market over the forecast period. Lack of standard treatment options, stringent regulatory framework may hinder the market for Autoimmune Drugs market globally.
Market Scope: Autoimmune Drugs Market
The Autoimmune Drugs Market is classified on the basis of drug class, distribution channel tested and geographical regions.
Based on Drug class, Autoimmune Drugs Market is segmented into
- Anti-Inflammatory Drugs
- Nonsteroidal anti-inflammatory drugs
Based on Distribution Channel, Autoimmune Drugs Market is segmented into
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
- Rest of Europe
- Australia & New Zealand
- ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
- South Korea
- Rest of Asia-Pacific
- Rest of Latin America
Middle East and Africa (MEA)
- Gulf Cooperation Council (GCC) Countries
- South Africa
- Rest of MEA
Market Summary: Autoimmune Drugs Market
Global Autoimmune Drugs market is expected to grow at significant rate owing to growing rates of autoimmune diseases. According to National Multiple Sclerosis Society (MS), approximately, 2.3 Mn people are living with multiple sclerosis worldwide. The market is composed of multinational and local companies involved in offering Autoimmune Drugs. Major players are involving in R&D for development and introduction of new drugs into the market. Market players are collaborating in order to develop the new molecules for the autoimmune diseases and further increasing their market portfolio. Furthermore, government and non-profit organizations are taking initiatives to increase the awareness and involving in development of drugs for autoimmune diseases.
Regional Analysis: Autoimmune Drugs Market
Geographically Autoimmune Drugs Market is segmented as Latin America, North America, Asia- Pacific, The Middle East & Africa and Europe. North America expected to be major market for Autoimmune Drugs owing to increase in prevalence of autoimmune disorders, presence of many market players, and government initiatives to promote the autoimmune disease awareness. Europe is expected to be another major market for global Autoimmune Drugs because of growing awareness and rising prevalence of autoimmune diseases. Asia Pacific expected to grow at faster rates owing to expansion of MNC’s into the developing countries of the regions such as India and increase in R&D investment.
Market participants: Autoimmune Drugs Market
Some of the players in Autoimmune Drugs Market
- Allergan, Inc. (S.)
- AbbVie Inc., (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- Bayer AG (Switzerland)
- Pfizer Inc. (US)
- Reddys (India)
- Novartis (Switzerland)
- Sanofi Avemtis (France)
- Eli Lilly (US)